Substance / Medication

Labetalol hydrochloride

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Research Evidence

Published studies and systematic reviews

Sort:
Clinical Evaluation of Pinggan Yiqi Yangshen Recipe Combined with Labetalol Hydrochloride and Magnesium Sulfate in the Treatment of PIH.
Li Ping, Zhao Jie, Gao Peipei et al. · Evid Based Complement Alternat Med · 2021
PMID: 34745277OtherFull text (PMC)
Electrochemical Quantitative Assessment of Labetalol Hydrochloride in Pure Form and Combined Pharmaceutical Formulations.
Salem Maissa Yacoub, Hassan Nagiba Yehia, Fayez Yasmin Mohamed et al. · Acta Chim Slov · 2020
PMID: 33855568Other
Derivatization of labetalol hydrochloride for its spectrofluorimetric and spectrophotometric determination inhuman plasma: Application to stability study.
Omar Mahmoud A, Derayea Sayed M, Abdel-Lateef Mohamed A et al. · Spectrochim Acta A Mol Biomol Spectrosc · 2018
PMID: 28961530Other
Transdermal drug delivery of labetalol hydrochloride: Feasibility and effect of penetration enhancers.
Zafar Saqib, Ali Asgar, Aqil Mohammed et al. · J Pharm Bioallied Sci · 2010
PMID: 21180464OtherFull text (PMC)
Formulation and evaluation of a gastroretentive dosage form of labetalol hydrochloride.
Garse Harshal, Vij Mohit, Yamgar Manohar et al. · Arch Pharm Res · 2010
PMID: 20361305Other
Hydrogel-forming microarray patches combined with powder-based reservoir for labetalol hydrochloride transdermal delivery.
Anjani Qonita Kurnia, Detamornrat Usanee, Larrañeta Eneko et al. · Int J Pharm · 2025
PMID: 39653288Preclinical
Metabolic Activation and Cytotoxicity of Labetalol Hydrochloride Mediated by Sulfotransferases.
Yang Lan, Xin Lihua, Shi Junzu et al. · Chem Res Toxicol · 2021
PMID: 33872499Preclinical
In vitro and in vivo assessment of matrix type transdermal therapeutic system of labetalol hydrochloride.
Mittal Ashu, Parmar Shikha, Singh Brijendra · Curr Drug Deliv · 2009
PMID: 19863491Preclinical

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Labetalol hydrochloride (substance)
SNOMED CT
50627005
UMLS CUI
C0699440

Clinical Data

This intervention maps to 15 entities in the Healos knowledge graph.

4
Conditions
7
Biomarkers
3
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.